


NCT05631574: Phase I/Ib Study of BMF-219, an oral covalent menin inhibitor, in patients with KRAS Mutant, Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer (PDAC), and Colorectal Carcinoma (CRC)

Dose Escalation

3+3 for Safety

Dose Expansion

Safety & Efficacy



Study Treatment

BMF-219

BMF-219, a covalent small molecule menin inhibitor, administered orally daily in 28-day cycles

Objectives

Primary

Determine OBD & RP2D of BMF-219 monotherapy independently for each indication

Secondary

- Evaluate safety and tolerability of BMF-219
- Determine PK/ PD parameters of BMF-219
- Explore additional evidence of efficacy and antitumor activity activity in in NSCLC, PDAC & CRC

Key Eligibility

- Age 18+
- Unresectable, locally advanced or metastatic disease with documented activating KRAS mutation
- Documented progression with measurable disease as defined by RECIST 1.1
- Prior treatment with KRAS inhibitor is permitted
- Adequate organ function with prior treatment-related toxicities resolved to ≤ Grade 2
- Prior systemic therapy: ≥1L PDAC & CRC, 2-4L NSCLC
- ECOG: 0-1 PDAC, 0-2 NSCLC & CRC
- Additional eligibility criteria apply.




We Aim to Cure™

Biomea Fusion, Inc.

900 Middlefield Road, 4th floor
Redwood City, CA 94063
1 (650) 980-9099
ClinicalTrials@biomeafusion.com

COVALENT-102



biomeafusion.com